Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XLGB dose-response study in postmenopausal osteoporosis
ChiCTR-TRC-05000347Phase 4Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Oct 2005
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of xianlinggubao in postmenopausal osteoporosis (3 arms), sponsored by The Chinese University of Hong Kong. Primary endpoints: Adverse events and Lumbar spine bone mineral density. Started Oct 2005; status: completed.
02
Drugs
xianlinggubao
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on ChiCTR-TRC-05000347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-05000347.